FROM THE EDITOR
The Thomson Reuters Institute’s 2026 State of the Corporate Law Department Report dropped a number that should stop every CLO cold: 86% of GCs say legal is a significant contributor to the business. Only 17% of other C-suite executives agree. Forty-two percent say legal contributes little or nothing.
That is not a data anomaly. That is a structural problem, and it is yours to solve.
I spent 26 years at the GC/CLO level in specialty pharma and biotech. I have been in that room, at that table, defending the department’s value to a CEO who wanted a head count reduction and a CFO who thought outside counsel billing was the only number that mattered. I know exactly how that conversation feels. What I want to tell you in this issue is what I wish someone had told me earlier: the perception gap is not about the work you are doing. It is about how you are organizing the department, and whether the CEO sees legal as an enabler or a tollbooth.
The analysis in this article draws on the Thomson Reuters 2026 State of the Corporate Law Department Report, the CLOC 2026 State of the Industry Report, Taylor Root’s 2026 US In-House Legal Restructuring Survey, and publicly available data on in-house legal hiring and department structure trends. No client information.
THE 42% PROBLEM
Here is what the data actually says.
Regulatory compliance workload in in-house legal departments rose 63% last year. Cybersecurity workload rose 58%. Budget and headcount growth are flat. Outside counsel spending expectations dropped from 58% of departments projecting increases to 37%. Only 32% of departments expect attorney headcount growth this year.
You are being asked to do more with less while the regulatory environment is producing more complexity, not less. If you are a pharma or biotech CLO, that is not abstract — you have lived through 232 tariffs, an FDA-SEC information-sharing MOU, three warning letters in a week targeting different contractor types, and a compounding enforcement theory that did not exist 18 months ago. The law is moving.
The C-suite does not see any of that as legal’s contribution. They see it as noise. And the reason they see it as noise is that most legal departments are still organized to absorb problems, not to prevent them. The tollbooth model, legal reviews things after the business brings them, produces exactly the perception the survey describes: legal as the department that slows things down and says no.
The 42% are not wrong about what they are experiencing. They are wrong about what it would take to change it.
WHAT RESTRUCTURING ACTUALLY LOOKS LIKE
The Taylor Root 2026 survey documents what the departments fixing this perception gap are doing differently. Three structural shifts are worth your attention.
Embedding, not reviewing. The departments closing the C-suite perception gap are placing lawyers inside business units: in the commercial team, in the clinical team, in the supply chain function before decisions get made. The embedded lawyer can surface legal risk before the contract is signed, before the product decision is made, before the FDA submission is finalized. In other words, at the point where it is cheapest to address. The GC who reviews things after the fact is a tollbooth. The lawyer embedded in the business team is an asset.
This is a structural change, not a cultural one. It requires headcount decisions and reporting-line clarity that most organizations have not made.
Specialists over generalists. The same survey shows demand for in-house specialists — data privacy, IP, regulatory affairs, government investigations — outpacing supply. Generalist-heavy departments are running short on the precise skills the business needs at the moments of highest risk. The fix is not hiring more generalists; it is building a staffing model that uses outside counsel or flexible counsel for routine volume and keeps in-house headcount concentrated on the highest-stakes specialty work.
For pharma and biotech CLOs, this maps directly onto the regulatory environment. The FDA-SEC MOU (see TGP, 11/1/26) is not a generalist problem, it requires someone who can run a simultaneous disclosure and enforcement analysis. The Section 232 tariff exposure (see, TGP, 11/4/26) is not a generalist problem, it requires customs, contracts, and regulatory expertise operating in the same room. If your department is organized around generalist coverage, you will be reactive on both.
Metrics that the CEO can read. Legal departments restructuring for C-suite credibility are building performance metrics, i.e. turnaround times, matter volume, budget variance, risk outcome tracking, and presenting them in business terms. This is not about proving that legal is busy. It is about demonstrating that legal is managing risk in a way the CFO and CEO can track. The difference between “we reviewed 847 contracts this quarter” and “we identified and remediated 23 tariff exposure provisions in supply agreements before the September 29 rate effective date” is the difference between overhead and contribution.
THE LIFE SCIENCES TIMING QUESTION
The Pharmaphorum analysis of GC-hire timing in life sciences raises a question that every pre-commercial and growth-stage biotech CLO should think through carefully: not when to bring on the GC, but what the GC’s mandate looks like once they arrive.
The article’s finding is correct but incomplete. It correctly identifies the trigger-event model — hire the GC at clinical trial launch, or at a significant financing round, or at an IPO. What it does not address is what happens to the mandate after those events are behind you. The GC hired for the IPO is not necessarily the right organizational model for a commercial-stage company facing active FDA enforcement, a supply chain under tariff pressure, and an activist investor landscape in which 34% of concluded life sciences campaigns since January 2024 preceded the company’s acquisition or dissolution.
The mandate has to evolve, and the department structure has to evolve with it. Here is what that progression looks like in practice:
Pre-IND / Series A: Outside counsel-heavy. A fractional GC or interim GC focused on IP protection, early licensing, and investor documentation makes more sense than a full-time hire. The CLOC data supports this — flexible counsel use is growing fastest in companies at this stage, partly because the work is episodic and partly because the talent is expensive.
Clinical stage / Series B-C: First permanent GC hire. The mandate at this stage is primarily clinical trial agreements, vendor contracts, IP prosecution oversight, and regulatory submissions. The department is typically one or two lawyers and a paralegal, with outside counsel handling anything requiring deep specialty expertise.
Commercial stage / pre- or post-IPO: This is where the department structure either evolves or breaks. The commercial-stage CLO faces a fundamentally different risk profile than the clinical-stage GC: active FDA oversight, payer and pricing risk, securities law obligations, employment law at scale, and M&A either as buyer or target. The department that handled Phase 2 trials is not sized or structured for this. The CLO who does not make the case for restructuring at this inflection point will be managing the 42% problem two years later.
THE CASE YOUR CEO NEEDS TO HEAR
The C-suite perception gap will not close by doing better legal work. It will close by changing how the work is organized and how its value is communicated.
The case has three parts:
Prevention has a dollar value. A single FDA warning letter costs between $5M and $50M in remediation, depending on severity. A securities disclosure failure that becomes an SEC enforcement referral — which is now structurally easier given the FDA-SEC MOU — carries both direct financial exposure and reputational cost. A CVR definition that gets litigated by a PE buyer who controls the milestone calculations is a loss you will not see coming. Each of these is a legal problem that was preventable. The embedded legal model identifies the exposure before it becomes the cost.
Outside counsel is not a substitute for in-house judgment. The non-delegation doctrine that FDA applied in the AI compliance warning letter (see TGP, 10/11/2026) applies equally to legal oversight: the company’s judgment obligation does not transfer to outside counsel, however capable. When the CEO says “we have outside counsel for that,” the right response is a clear account of what outside counsel does not know — the company’s regulatory history, the pending FDA inspection, the CFO’s read on the pipeline, the board’s risk tolerance. That institutional knowledge lives in-house or it does not exist.
The department structure is a strategic decision. Embedding lawyers in business units, building a specialist-heavy model, investing in legal operations and metrics — these are capital allocation decisions, not departmental preferences. The CLO who presents them as such, with a business case in the CEO’s terms, is the CLO who closes the perception gap. The CLO who presents them as a request for more resources is the CLO who gets a head count reduction.
BOX: THE RESTRUCTURING DIAGNOSTIC
Before you redesign the department, answer these six questions:
What is your matter volume by category, and where is it growing? Regulatory compliance and cybersecurity are the two fastest-growing categories nationally. What are they in your company?
Where does legal learn about problems? If the answer is “when someone brings it to us,” you are running a tollbooth model. If the answer is “we are embedded in the team that makes the decision,” you are running a prevention model.
How is outside counsel being used? Routine volume work handled by outside counsel at $600/hour is a budget problem. Specialty work handled by outside counsel that the in-house team then manages is a model.
What can the CEO read in your quarterly report? If the answer is a list of matters and billing, that is an overhead report. If the answer is risk outcomes and business enablement, that is a contribution report.
Who is the second lawyer? If the answer to the question “what happens if the GC leaves” is “we call outside counsel,” you do not have a legal department. You have a GC.
What is the stage-specific risk profile for the next 18 months? The department should be sized and structured for where the company is going, not where it has been.
WORKSTREAM 1 — IMMEDIATE: Run the Perception Diagnostic
Survey your C-suite peers anonymously on two questions: Does legal contribute to business outcomes? Does legal make decisions faster or slower? The answers will tell you whether you have a structural problem or a communication problem. They are different interventions.
BUSINESS IMPACT: The 42% perception finding is a CLO retention risk and a budget risk. C-suites that do not believe legal contributes significantly make different head count decisions than ones that do.
WORKSTREAM 2 — NEAR-TERM: Map the Matter Volume and Restructure Around It
Pull your last 12 months of matter volume by category, by origin (who brought the matter), and by time-to-resolution. Identify the three categories with the highest volume growth rate. Those are the candidates for embedding or specialist coverage. Present the restructuring case in budget terms.
BUSINESS IMPACT: Departments that have done this restructuring are reporting faster decision-making and reduced outside counsel spend on routine matters, with in-house capacity freed for strategic work.
WORKSTREAM 3 — STRATEGIC: Build the CLO Dashboard
Build a quarterly CLO dashboard in business terms: risk events identified and remediated (with estimated avoided cost); transaction support (with deal value and timeline); regulatory matters (with enforcement exposure quantified); outside counsel spend vs. in-house headcount cost ratio. Present it to the board, not just the CEO.
BUSINESS IMPACT: The board presentation of a CLO dashboard is the most direct structural intervention on the C-suite perception gap. It changes the audience and the accountability frame simultaneously.
“86% of GCs say legal is a significant contributor to the business. 42% of other C-suite executives say legal contributes little or nothing. That gap does not close by doing better legal work. It closes by organizing the work differently.”
I’ve created a CLO Department Restructuring Toolkit for readers interested in applying these cocepts to their functions. It can be found at https://laroccaadvisory.gumroad.com/l/igejy
COMING NEXT
We are turning to the SCOTUS finale on the skinny label — Hikma v. Amarin, decided June 4, 9-0, Justice Jackson writing. The Court held that a section viii carve-out plus ordinary marketing does not plausibly plead inducement; liability requires affirmative, purposeful steps to encourage infringement. Amarin dropped its suit in October. What the decision means for every generic strategy built around carve-out labels — and what your outside counsel’s inducement analysis should look like now.
ABOUT THE AUTHOR
John LaRocca is the founder of LaRocca Advisory Services, a fractional CLO practice serving PE-backed specialty pharma and commercial-stage biotech. He has served as GC/CLO at Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals (acquired by Alcon, ~$930M), and Y-mAbs Therapeutics (acquired by SERB, $412M at a 105% premium). He is a member of the New York and New Jersey bars and holds a J.D. and B.A. from Columbia University. He lives in Montclair, NJ.
The GC Playbook publishes weekly on Substack.


